SERA PROGNOSTICS, INC. (SERA) Spending and interest coverage
- R&D / revenue · 12 months: Value 18604.29%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 5615.71%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -5328.29×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 18604.29% | Research and development expense / revenue. Period ending 2026-06-30. $13.02M ÷ $70.00K × 100 ≈ 18604.29% |
| Stock-based compensation / revenue · 12 months | 5615.71% | Share-based compensation / revenue. Period ending 2026-06-30. $3.93M ÷ $70.00K × 100 ≈ 5615.71% |
| Interest coverage · 12 months | -5328.29× | Operating income ÷ reported interest expense. $-37.30M ÷ $7.00K ≈ -5328.29× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 13.02M USD | Research and Development Expense |
| Revenue | 70.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 3.93M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -37.30M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 7.00K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $13.02M | $70.00K | $3.93M | $-37.30M | $7.00K | 18604.29% | 5615.71% | -5328.29× | Reported |
| 2026-03-31 | $12.87M | $57.00K | $4.45M | $-36.61M | $7.00K | 22573.68% | 7810.53% | -5230.57× | Reported |
| 2025-12-31 | $13.17M | $81.00K | $5.11M | $-36.50M | $9.00K | 16260.49% | 6308.64% | -4056.00× | Reported |
| 2025-09-30 | $13.09M | $95.00K | $5.71M | $-36.97M | $14.00K | 13783.16% | 6008.42% | -2640.93× | Reported |
| 2025-06-30 | $13.31M | $108.00K | $6.13M | $-36.85M | $17.00K | 12325.93% | 5679.63% | -2167.94× | Reported |
| 2025-03-31 | $14.38M | $115.00K | $6.81M | $-36.79M | $23.00K | 12505.22% | 5924.35% | -1599.48× | Reported |
| 2024-12-31 | $14.73M | $77.00K | $7.01M | $-36.63M | $28.00K | 19129.87% | 9107.79% | -1308.39× | Reported |
| 2024-09-30 | $15.49M | $94.00K | $6.74M | $-36.06M | (m) | 16474.47% | 7173.40% | (m) | (m) |
| 2024-06-30 | $15.52M | $107.00K | $6.25M | $-35.38M | (m) | 14507.48% | 5836.45% | (m) | (m) |
| 2024-03-31 | $14.80M | $206.00K | $5.66M | $-37.59M | (m) | 7186.89% | 2748.54% | (m) | (m) |
| 2023-12-31 | $15.22M | $306.00K | $5.27M | $-39.82M | (m) | 4975.49% | 1723.20% | (m) | (m) |
| 2023-09-30 | $14.81M | $330.00K | $5.27M | $-41.39M | (m) | 4489.39% | 1596.06% | (m) | (m) |
| 2023-06-30 | $15.45M | $375.00K | $5.36M | $-44.40M | (m) | 4120.53% | 1430.13% | (m) | (m) |
| 2023-03-31 | $15.03M | $330.00K | $5.14M | $-44.68M | (m) | 4553.03% | 1556.67% | (m) | (m) |
| 2022-12-31 | $14.24M | $268.00K | $5.05M | $-45.65M | (m) | 5314.93% | 1886.19% | (m) | (m) |
| 2022-09-30 | $13.83M | $229.00K | $4.83M | $-47.78M | (m) | 6041.05% | 2107.86% | (m) | (m) |
| 2022-06-30 | $12.38M | $165.00K | $4.46M | $-46.03M | (m) | 7503.64% | 2704.85% | (m) | (m) |
| 2022-03-31 | $11.95M | $107.00K | $4.11M | $-41.67M | (m) | 11163.55% | 3843.93% | (m) | (m) |
| 2021-12-31 | $11.02M | $82.00K | $3.13M | $-35.40M | (m) | 13437.80% | 3817.07% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $7.78M | $25.00K | $726.00K | $-17.97M | (m) | 31128.00% | 2904.00% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |